SSRI Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says
You may also be interested in...
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.